No Data
US Stock MarketDetailed Quotes
PCRX Pacira BioSciences
Watchlist
28.490
+0.680+2.45% Close 12/04 16:00 ET
28.4900.0000.00%
Post 17:29 ET
29.115High27.770Low393.79KVolume
27.890Open27.810Pre Close11.28MTurnover0.86%Turnover Ratio189.93P/E (TTM)1.32BMarket Cap48.60052wk High83.79P/E (Static)46.44MShares25.93052wk Low1.59P/B1.31BFloat Cap121.950Historical High--Dividend TTM45.82MShs Float6.160Historical Low--Div YieldTTM4.84%Amplitude28.634Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Pacira BioSciences Company
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
EXPAREL536.9M80.52%
ZILRETTA105.52M15.82%
Iovera°15.26M2.29%
Bupivacaine liposome injectable suspension6.48M0.97%
Royalty revenue2.67M0.40%
News
The Three-year Earnings Decline Is Not Helping Pacira BioSciences' (NASDAQ:PCRX Share Price, as Stock Falls Another 4.3% in Past Week
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But the last three years have been particularly tough on longer term Pacira BioScien
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor canal block and
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies
Comments
The market seems to tolerate EPS decline but last year's worse-than-average performance may indicate long term investor concerns.
The Three-year Earnings Decline Is Not Helping Pacira BioSciences' (NASDAQ:PCRX Share Price, as Stock Falls Another 4.3% in Past Week
$Pacira BioSciences(PCRX.US$$Flexion Therapeutics Inc(FLXN.US$ On October 12, Pacira BioSciences announced that it has entered into a definitive agreement to acquire Flexion Therapeutics For $8.50 per share, or approximately $430 million, in cash to enhance its non-opioid pain portfolio. The deal also includes contingent valuable rights worth up to $8.00 per share, which are tied to Zilretta sales targets and FDA approvals for FX201 and FX301.
3
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--